| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
|
N Engl J Med
|
2008
|
13.06
|
|
2
|
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
|
Lancet Oncol
|
2006
|
8.53
|
|
3
|
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
|
J Clin Oncol
|
2010
|
5.20
|
|
4
|
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
|
J Natl Cancer Inst
|
2009
|
3.83
|
|
5
|
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
|
Lancet Oncol
|
2011
|
2.87
|
|
6
|
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
|
Lancet Oncol
|
2008
|
2.34
|
|
7
|
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
|
J Clin Oncol
|
2010
|
2.24
|
|
8
|
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
2.13
|
|
9
|
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
|
Blood
|
2010
|
2.09
|
|
10
|
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
|
Lancet Oncol
|
2011
|
1.81
|
|
11
|
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
|
J Clin Oncol
|
2012
|
1.66
|
|
12
|
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
|
J Clin Oncol
|
2009
|
1.54
|
|
13
|
Non-Hodgkin's lymphoma and residential proximity to toxic industrial waste in southern Israel.
|
Haematologica
|
2005
|
1.54
|
|
14
|
Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis.
|
J Clin Oncol
|
2008
|
1.52
|
|
15
|
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
|
Blood
|
2012
|
1.50
|
|
16
|
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
|
J Clin Oncol
|
2012
|
1.50
|
|
17
|
Clinical and epidemiologic investigation of two Legionella-Rickettsia co-infections.
|
Isr Med Assoc J
|
2003
|
1.44
|
|
18
|
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.
|
Am J Kidney Dis
|
2008
|
1.42
|
|
19
|
Myeloma in scar tissue--an underreported phenomenon or an emerging entity in the novel agents' era? A single center series.
|
Acta Haematol
|
2014
|
1.39
|
|
20
|
High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia.
|
Acta Haematol
|
2015
|
1.38
|
|
21
|
Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.
|
Leuk Lymphoma
|
2003
|
1.35
|
|
22
|
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
|
J Natl Cancer Inst
|
2011
|
1.34
|
|
23
|
Non-Hodgkin's lymphomas of the colon.
|
Isr Med Assoc J
|
2006
|
1.33
|
|
24
|
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
|
J Clin Oncol
|
2011
|
1.30
|
|
25
|
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.
|
Haematologica
|
2009
|
1.20
|
|
26
|
The late adverse events of rituximab therapy--rare but there!
|
Leuk Lymphoma
|
2009
|
1.17
|
|
27
|
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
|
Eur J Haematol
|
2010
|
1.15
|
|
28
|
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
|
Br J Haematol
|
2014
|
1.11
|
|
29
|
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
|
Haematologica
|
2009
|
1.11
|
|
30
|
Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
|
Am J Hematol
|
2009
|
1.10
|
|
31
|
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
|
J Clin Oncol
|
2012
|
1.10
|
|
32
|
Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.
|
Am J Hematol
|
2012
|
1.08
|
|
33
|
Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials.
|
Acta Oncol
|
2012
|
1.04
|
|
34
|
Current multiple myeloma treatment strategies with novel agents: a European perspective.
|
Oncologist
|
2010
|
1.04
|
|
35
|
Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis.
|
Cancer
|
2010
|
1.03
|
|
36
|
Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.
|
PLoS One
|
2012
|
1.00
|
|
37
|
Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.
|
Leuk Lymphoma
|
2009
|
0.99
|
|
38
|
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
|
Eur J Haematol
|
2011
|
0.99
|
|
39
|
Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission.
|
Leuk Res
|
2004
|
0.96
|
|
40
|
Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
|
Acta Haematol
|
2008
|
0.93
|
|
41
|
The anti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways.
|
Br J Haematol
|
2009
|
0.92
|
|
42
|
Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
|
Leuk Res
|
2009
|
0.92
|
|
43
|
Early death in patients diagnosed with non-Hodgkin's lymphoma.
|
Ann Hematol
|
2012
|
0.90
|
|
44
|
The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.
|
Cancer Biol Ther
|
2011
|
0.90
|
|
45
|
ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis.
|
Acta Haematol
|
2009
|
0.90
|
|
46
|
Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation.
|
Cochrane Database Syst Rev
|
2008
|
0.90
|
|
47
|
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2003
|
0.89
|
|
48
|
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
|
Clin Cancer Res
|
2013
|
0.89
|
|
49
|
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.
|
Cochrane Database Syst Rev
|
2012
|
0.88
|
|
50
|
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
|
Am J Hematol
|
2009
|
0.87
|
|
51
|
Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.
|
Leuk Lymphoma
|
2007
|
0.86
|
|
52
|
Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation.
|
J Infect
|
2013
|
0.85
|
|
53
|
Neutropenia after rituximab treatment: new insights on a late complication.
|
Curr Opin Hematol
|
2012
|
0.85
|
|
54
|
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
|
PLoS One
|
2013
|
0.84
|
|
55
|
Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
|
Leuk Lymphoma
|
2013
|
0.84
|
|
56
|
High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel.
|
Br J Haematol
|
2003
|
0.84
|
|
57
|
Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
|
Haematologica
|
2012
|
0.84
|
|
58
|
Acute promyelocytic leukemia with a smoldering course associated with therapy-related myelodysplastic syndrome.
|
Acta Haematol
|
2011
|
0.84
|
|
59
|
Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis.
|
Thorax
|
2010
|
0.83
|
|
60
|
Rituximab as maintenance therapy for patients with follicular lymphoma.
|
Cochrane Database Syst Rev
|
2009
|
0.83
|
|
61
|
Measles antibody prevalence rates among young adults in Israel.
|
Am J Infect Control
|
2002
|
0.82
|
|
62
|
Expression of CD24 on CD19- CD79a+ early B-cell progenitors in human bone marrow.
|
Cell Immunol
|
2005
|
0.82
|
|
63
|
A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation.
|
Apoptosis
|
2008
|
0.81
|
|
64
|
A mutation in LMAN1 (ERGIC-53) causing combined factor V and factor VIII deficiency is prevalent in Jews originating from the island of Djerba in Tunisia.
|
Blood Coagul Fibrinolysis
|
2004
|
0.81
|
|
65
|
Surveillance of infectious complications in hemato-oncological patients.
|
Isr Med Assoc J
|
2009
|
0.81
|
|
66
|
Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
|
Cochrane Database Syst Rev
|
2013
|
0.81
|
|
67
|
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
|
Clin Pharmacokinet
|
2011
|
0.80
|
|
68
|
Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.
|
Int J Antimicrob Agents
|
2012
|
0.80
|
|
69
|
Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
|
Exp Hematol
|
2010
|
0.80
|
|
70
|
High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
|
Am J Hematol
|
2011
|
0.80
|
|
71
|
NAD(P)H quinone oxidoreductase protects TAp63gamma from proteasomal degradation and regulates TAp63gamma-dependent growth arrest.
|
PLoS One
|
2010
|
0.80
|
|
72
|
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
|
Leuk Lymphoma
|
2010
|
0.80
|
|
73
|
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.
|
Cochrane Database Syst Rev
|
2011
|
0.80
|
|
74
|
Trends and challenges in searching for HLA-matched unrelated donors in Israel.
|
Hum Immunol
|
2013
|
0.79
|
|
75
|
Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.
|
Am J Hematol
|
2014
|
0.79
|
|
76
|
Burkitt's lymphoma of the ovary: case report and review of the literature.
|
Acta Haematol
|
2012
|
0.79
|
|
77
|
Hodgkin lymphoma and hypothermia: case report and review of the literature.
|
Acta Haematol
|
2013
|
0.79
|
|
78
|
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
|
Cochrane Database Syst Rev
|
2012
|
0.78
|
|
79
|
Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.
|
Cancer Lett
|
2012
|
0.78
|
|
80
|
Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.
|
Acta Oncol
|
2014
|
0.77
|
|
81
|
Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling.
|
Leuk Res
|
2013
|
0.77
|
|
82
|
Prevalence of iron deficiency and anemia among strenuously trained adolescents.
|
J Adolesc Health
|
2005
|
0.77
|
|
83
|
Multifactorial activities of nonsteroidal antiestrogens against leukemia.
|
Cancer Detect Prev
|
2003
|
0.77
|
|
84
|
18F-fluorodeoxyglucose-Avid mammary mass in a patient with insulin-dependent diabetes mellitus and Hodgkin's lymphoma: relapse or pitfall?
|
Isr Med Assoc J
|
2006
|
0.77
|
|
85
|
Management of aplastic anemia: the role of systematic reviews and meta-analyses.
|
Acta Haematol
|
2010
|
0.77
|
|
86
|
Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient with acute lymphoblastic leukemia.
|
Isr Med Assoc J
|
2012
|
0.77
|
|
87
|
The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.
|
Cochrane Database Syst Rev
|
2013
|
0.76
|
|
88
|
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
|
Br J Haematol
|
2011
|
0.76
|
|
89
|
Is classical Hodgkin's disease indeed a single entity?
|
Leuk Lymphoma
|
2002
|
0.76
|
|
90
|
Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
|
Isr Med Assoc J
|
2009
|
0.76
|
|
91
|
Rituximab maintenance for follicular lymphoma.
|
Nat Rev Clin Oncol
|
2010
|
0.75
|
|
92
|
Re: Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis.
|
J Natl Cancer Inst
|
2004
|
0.75
|
|
93
|
Clinical utility gene card for: familial polycythaemia vera.
|
Eur J Hum Genet
|
2012
|
0.75
|
|
94
|
Incidence of anemia and iron deficiency in strenuously trained adolescents: results of a longitudinal follow-up study.
|
J Adolesc Health
|
2009
|
0.75
|
|
95
|
Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
|
Transplantation
|
2013
|
0.75
|
|
96
|
Immunotherapy for patients with follicular lymphoma: the contribution of systematic reviews.
|
Acta Haematol
|
2010
|
0.75
|
|
97
|
Limited positron emission tomography-computed tomography for restaging of lymphoma: a strategy for reducing radiation exposure among patients with early-stage curable lymphoma.
|
Acta Haematol
|
2013
|
0.75
|
|
98
|
Debulking surgery for patients with diffuse large B-cell non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
99
|
Incidental asthma prevention by immune serum globulin.
|
Ann Allergy Asthma Immunol
|
2002
|
0.75
|
|
100
|
Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
|
Clin Transplant
|
2012
|
0.75
|
|
101
|
Is bone marrow biopsy obligatory in all patients with non-Hodgkin's lymphoma?
|
Acta Haematol
|
2007
|
0.75
|
|
102
|
The role of ¹⁸F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia.
|
Leuk Res
|
2013
|
0.75
|
|
103
|
Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
|
Hematol Oncol
|
2014
|
0.75
|
|
104
|
Involvement of proteases in the action of IFN-gamma on WISH cells.
|
J Interferon Cytokine Res
|
2002
|
0.75
|
|
105
|
Cycle ergometry estimation of physical fitness among Israeli soldiers.
|
Mil Med
|
2004
|
0.75
|
|
106
|
Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure.
|
Leuk Res
|
2013
|
0.75
|
|
107
|
Total therapy-based treatment for multiple myeloma--a single center experience.
|
Ann Hematol
|
2009
|
0.75
|
|
108
|
Induction of death of leukemia cells by TW-74, a novel derivative of chloro-naphthoquinone.
|
Anticancer Res
|
2013
|
0.75
|
|
109
|
Allogeneic hematopoietic cell transplantation for adult patients with acute leukemia: the role of meta-analyses.
|
Acta Haematol
|
2010
|
0.75
|
|
110
|
The use of myeloid colony-stimulating factors in hematologic malignancies: the role of systematic reviews and meta-analyses.
|
Acta Haematol
|
2010
|
0.75
|
|
111
|
The prevalence of low hemoglobin values among new infantry recruits and nonlinear relationship between hemoglobin concentration and physical fitness.
|
Am J Hematol
|
2007
|
0.75
|
|
112
|
Adult infection with hepatitis A despite declining endemicity; in favor of adult vaccination.
|
Vaccine
|
2002
|
0.75
|